Metagenomi Therapeutics, Inc. — All Filings
130 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
424B4
8-A12B
8-K
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
S-1
S-1/A
S-3
S-8
SC 13G
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0000950170-25-040238 | Mar 17, 2025 | — |
| 10-K | 10-K | 0000950170-25-040217 | Mar 17, 2025 | Dec 31, 2024 |
| 4 | 4 | 0000950170-25-035566 | Mar 7, 2025 | Mar 5, 2025 |
| 4 | 4 | 0000950170-25-035565 | Mar 7, 2025 | Mar 5, 2025 |
| 4 | 4 | 0000950170-25-014528 | Feb 5, 2025 | Feb 3, 2025 |
| 3 | 3 | 0000950170-25-009328 | Jan 27, 2025 | — |
| 8-K | 8-K | 0000950170-25-006028 | Jan 16, 2025 | Jan 13, 2025 |
| 8-K | 8-K | 0000950170-24-134733 | Dec 10, 2024 | Dec 9, 2024 |
| 4 | 4 | 0000950170-24-134124 | Dec 6, 2024 | Dec 5, 2024 |
| 8-K | 8-K | 0000950170-24-126317 | Nov 13, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-126273 | Nov 13, 2024 | Sep 30, 2024 |
| SC 13G | SC 13G | 0001104659-24-114820 | Nov 6, 2024 | — |
| 4 | 4 | 0000950170-24-104439 | Sep 6, 2024 | Sep 5, 2024 |
| 8-K | 8-K | 0000950170-24-102805 | Sep 3, 2024 | — |
| 8-K | 8-K | 0000950170-24-096673 | Aug 14, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-096665 | Aug 14, 2024 | Jun 30, 2024 |
| 8-K | 8-K | 0000950170-24-059532 | May 14, 2024 | — |
| 10-Q | 10-Q | 0000950170-24-059504 | May 14, 2024 | Mar 31, 2024 |
| SC 13G | SC 13G | 0001104659-24-060040 | May 10, 2024 | — |
| 8-K | 8-K | 0000950170-24-051238 | May 1, 2024 | Apr 26, 2024 |
| 4 | 4 | 0000950170-24-041571 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041569 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041551 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041545 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041537 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041527 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041521 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041515 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041483 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041471 | Apr 3, 2024 | Apr 1, 2024 |
| 4 | 4 | 0000950170-24-041449 | Apr 3, 2024 | Apr 1, 2024 |
| 8-K | 8-K | 0000950170-24-036847 | Mar 27, 2024 | — |
| 10-K | 10-K | 0000950170-24-036838 | Mar 27, 2024 | Dec 31, 2023 |
| 4 | FORM 4 SUBMISSION | 0001209191-24-003423 | Feb 15, 2024 | Feb 9, 2024 |
| 4 | PRIMARY DOCUMENT | 0001578563-24-000080 | Feb 15, 2024 | Feb 13, 2024 |
| 3 | PRIMARY DOCUMENT | 0001578563-24-000079 | Feb 15, 2024 | Feb 8, 2024 |
| 4 | 4 | 0000950170-24-015269 | Feb 14, 2024 | Feb 13, 2024 |
| 8-K | 8-K | 0001193125-24-033697 | Feb 13, 2024 | — |
| 424B4 | 424B4 | 0001193125-24-031007 | Feb 12, 2024 | — |
| S-8 | S-8 | 0001193125-24-030109 | Feb 9, 2024 | — |
| SEC STAFF LETTER | — | 9999999997-24-000274 | Feb 8, 2024 | — |
| EFFECT | — | 9999999995-24-000355 | Feb 8, 2024 | — |
| 3 | FORM 3 SUBMISSION | 0001209191-24-003012 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012972 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012971 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012970 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012968 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012967 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012963 | Feb 8, 2024 | — |
| 3 | 3 | 0000950170-24-012959 | Feb 8, 2024 | — |